[1] PERRILLO R.Benefits and risks of interferon therapy for hepatitis B[J]. Hepatology，2009，49（5 Suppl）:S103-111.
[2] 汤伟亮，谢青.慢性乙型肝炎的干扰素治疗[J]. 中华肝脏病杂志，2009，17（10）：726-729.
[3] CHAN HL，WONG VW，CHIM AM，et al.Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B[J]. Aliment Pharmacol Ther，2010，32:1323-1331.
[4] BRUNETTO MR，MORICONI F，BONINO F，et al.Hepatitis B virus surface antigen levels:a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B[J]. Hepatology，2009，49:1141-1150.
[5] 中华医学会传染病与寄生虫病学分会，肝病学分会.病毒性肝炎防治方案[J]. 中华肝脏病杂志，2000，8:324-329.
[6] ANAND AC，PURI P.Treatment of chronic hepatitis B:will entecavir and telbivudine do the trick[J]. Trop Gastroentero1，2008，29:71-75.
[7] European Association For The Study Of The Liver.EASL clinical practice guidelines:management of chronic hepatitis B[J]. J Hepatol，2009，50:227-242.
[8] SYPSA VA，MIMIDIS K，TASSOPOULOS NC，et al.A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative[J]. Hepatology，2005，42:77-85.
[9] LEWIN SR，RIBEIRO RM，WALTERS T，et al.Analysis of hepatitis B viral load decline under potent therapy:complex decay profiles observed[J]. Hepatology，2001，34:1012-1020.
[10] CHEONG JY.Management of chronic hepatitis B in treatment naive patients[J]． Korean J GastroenteroJ，2008，51：338-345.
[11] CHAN HL，WONG VW，TSE AM，et al.Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response[J]. Clin Gastroenterol Hepatol，2007，5:1462-1468.
[12] AKMAN SA，OKCU SC，HALICIOGLU O，et al.Therapeutic efficacy of sequential and simultaneous treatments with interferon-alpha and lamivudine in children with chronic hepatitis B[J]. Pediatr Int，2007，49（6）：848.
[13] WONG DK，YUEN MF，YUAN H，et al.Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients[J]. Hepatology，2004，40:727-737. |
